Mirum Pharmaceuticals, Inc. (MIRM) Financial Analysis & Valuation | Quarter Chart
Mirum Pharmaceuticals, Inc. (MIRM)
MIRMPrice: $123
Fair Value: 🔒
🔒score
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intra... more
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commerciali... more
Description
Shares
| Market Cap | $6.17B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Christopher Peetz |
| IPO Date | 2019-07-18 | CAGR | — |
| Employees | 334 | Website | www.mirumpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MIRM chart loading...
Fundamentals
Technicals
| Enterprise Value | $6.61B | P/E Ratio | -9.04 |
| Forward P/E | -1405.71 | PEG Ratio | — |
| P/S Ratio | 12.98 | P/B Ratio | 35.8 |
| P/CF Ratio | -50.8 | P/FCF Ratio | -42.93 |
| EPS | $-13.61 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 50.19% | Gross Margin | 0.81% |
| Operating Margin | -0.12% | Profit Margin | -1.4% |
| ROE | -2.89% | ROA | -0.9% |
| ROCE | -0.11% | Current Ratio | 2.09 |
| Quick Ratio | 1.99 | Cash Ratio | 1.19 |
| Debt/Equity | 1.34 | Interest Coverage | -4.87 |
| Altman Z Score | 4.18 | Piotroski Score | 3 |